Measured Wealth Private Client Group LLC Has $522,000 Stock Position in Merck & Co., Inc. (NYSE:MRK)

Measured Wealth Private Client Group LLC decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 12.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,203 shares of the company’s stock after selling 870 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Merck & Co., Inc. were worth $522,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dubuque Bank & Trust Co. raised its holdings in Merck & Co., Inc. by 16.0% during the 1st quarter. Dubuque Bank & Trust Co. now owns 3,372 shares of the company’s stock worth $281,000 after purchasing an additional 464 shares during the last quarter. Burns J W & Co. Inc. NY increased its stake in shares of Merck & Co., Inc. by 3.7% in the 1st quarter. Burns J W & Co. Inc. NY now owns 7,449 shares of the company’s stock valued at $620,000 after acquiring an additional 267 shares during the last quarter. CX Institutional increased its stake in shares of Merck & Co., Inc. by 27.4% in the 1st quarter. CX Institutional now owns 5,365 shares of the company’s stock valued at $446,000 after acquiring an additional 1,155 shares during the last quarter. Tibra Equities Europe Ltd bought a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $8,051,000. Finally, Benson Investment Management Company Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% in the 1st quarter. Benson Investment Management Company Inc. now owns 45,082 shares of the company’s stock valued at $3,749,000 after acquiring an additional 245 shares during the last quarter. Institutional investors and hedge funds own 74.97% of the company’s stock.

In related news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

NYSE MRK traded up $1.67 during trading hours on Friday, reaching $85.43. 1,444,379 shares of the company’s stock were exchanged, compared to its average volume of 8,180,964. The company’s 50-day moving average is $84.58 and its two-hundred day moving average is $82.23. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.35. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21. The company has a market capitalization of $213.25 billion, a price-to-earnings ratio of 19.68, a price-to-earnings-growth ratio of 1.69 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The business had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. During the same period in the prior year, the business earned $1.06 EPS. Merck & Co., Inc.’s revenue for the quarter was up 12.4% compared to the same quarter last year. Research analysts predict that Merck & Co., Inc. will post 4.92 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a yield of 2.58%. Merck & Co., Inc.’s payout ratio is 50.69%.

A number of analysts have recently commented on MRK shares. Mizuho reaffirmed a “buy” rating and issued a $97.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, September 8th. Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Svb Leerink started coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price target for the company. Argus upped their price target on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Citigroup upped their price target on Merck & Co., Inc. from $84.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, June 21st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $93.29.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How liquidity affects the bid-ask spread

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit